ADP-ribosylation factor-like 4C predicts worse prognosis in endometriosis-associated ovarian cancers

Shiro Wakinoue, Wakinoue S, Tokuhiro Chano, Amano T, Tsukuru Amano, Takahiro Isono, Isono T, Fuminori Kimura, Kimura F, Kushima R, Ryoji Kushima, Takashi Murakami, Murakami T
Cancer biomarkers : section A of Disease markers · 2018 · vol. 24(2) , pp. 223–229 · doi:10.3233/cbm-181836 · PMID:30594917 · PMC13082491 · W2907150421
article OA: green CC0 ⤵ 3 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-07, 2026-07-09 ⓘ

High expression of ADP-ribosylation factor-like protein 4C (ARL4C) in endometriosis-associated ovarian cancers correlates with worse overall survival and progression-free survival.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Endometrioid ovarian carcinoma and clear cell ovarian carcinoma are both classified as endometriosis-associated ovarian cancer (EAOC). Despite the high rates of recurrence and mortality of EAOC, no prognostic biomarkers have been determined. ADP-ribosylation factor-like protein 4C (ARL4C) has been reported to be involved in various tumor progression processes, but its clinical significance for predicting prognosis in EAOC cases has never been studied. OBJECTIVE: The present study aimed to determine the clinical significance of ARL4C expression in EAOC prognosis. METHODS: ARL4C expression was semi-quantitatively evaluated via immunohistochemistry in 61 EAOC patients, and the correlations between ARL4C expression and clinicopathological data and survival were statistically analyzed. RESULTS: Thirty-six (59%) cases had high levels of ARL4C, which was related to worse 5-year overall survival (OS) (log-rank test, p= 0.036). In multivariate Cox proportional hazard model, high ARL4C expression was a significantly independent predictive factor for worse 5-year OS (hazard ratio = 12.048, p= 0.0201) and 5-year PFS (hazard ratio = 8.130, p= 0.0036). CONCLUSIONS: ARL4C is a biomarker for worse prognosis and a novel therapeutic target in EAOC.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

ADP-Ribosylation Factors Biomarkers, Tumor Carcinoma, Endometrioid Carcinoma, Endometrioid Ovarian Neoplasms Ovarian Neoplasms ADP-Ribosylation Factors ADP-Ribosylation Factors Adult Aged Aged, 80 and over Biomarkers, Tumor Biomarkers, Tumor Carcinoma, Endometrioid Carcinoma, Endometrioid Disease Progression Female Gene Expression Profiling Gene Expression Regulation, Neoplastic Humans

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (69)

Cited by (3)

Source provenance

crossref
last seen: 2026-05-19T01:00:17.311080+00:00
europepmc
last seen: 2026-08-09T06:10:49.860119+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:19:25.021412+00:00
License: CC0 · commercial use OK